Ambrx Biopharma Inc. AMAM
Day range unavailable
52-week range unavailable
- Market cap
- 1.77B
- Revenue (ttm)
- 4.09M
- Shares out
- 63.29M
- Forward P/E
- -17.95
- Analysts
- Hold
- Price target
- 28.67 (+2.4%)
- Earnings date
- Apr 4, 2024
Key statistics
- Enterprise value
- 1.55B
- PEG ratio
- -0.94
- Price / sales
- 432.96
- Price / book
- 7.28
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -96.70%
- Free cash flow
- -34.50M
- Total cash
- 225.26M
- Total debt
- 10.52M
- Return on equity
- -37.23%
- Short % of float
- 3.28%
- 50-day average
- 25.85
- 200-day average
- 18.23
Analyst view
Consensus: hold
- Target (low)
- 28.00
- Target (mean)
- 28.67
- Target (high)
- 30.00
- Strong buy1
- Buy2
- Hold5
- Sell0
- Strong sell0
Next earnings
Apr 4, 2024
Expected Apr 4, 2024. Consensus EPS estimate -0.40.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 4, 2024 | Dec 1, 2023 | -0.41 | — | — | — |
| Apr 25, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
About Ambrx Biopharma Inc.
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California. As of March 7, 2024, Ambrx Biopharma Inc. operates as a subsidiary of Johnson & Johnson.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ambrx.com
News
Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session 
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
Why Vistagen Therapeutics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket 
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023 - 12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023 
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023 - Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Nutanix, Cara Therapeutics, Tremor International And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Your note
Sign in to keep a note on AMAM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AROMANDO ANDREW | Chief Operating Officer | Stock Award(Grant) | Dec 10, 2023 | 109,263 |
| CORMORANT ASSET MANAGEMENT ,L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 22, 2023 | 0 |
| DALESANDRO MARGARET | Director | Stock Award(Grant) | Aug 31, 2023 | 195,833 |
| GLOVER STEPHEN C | Director | Stock Award(Grant) | Jun 6, 2023 | 85,000 |
| HERMANS KATE | Director | Stock Award(Grant) | Jun 6, 2023 | 85,000 |
| NELSON SONJA | Chief Financial Officer | Stock Award(Grant) | Dec 10, 2023 | 545,776 |